-
13m 47sPart 2 | Session 6 BHF PROTECT-TAVI: Cerebral Embolic Protection in TAVI
-
4m 15sPart 3 | Session 1 The Phase 3 REVERSE-IT Trial
-
4m 3sPart 3 | Session 2 EVOLUT Low Risk: 5Y Outcomes After TAVR or SAVR in Low-Risk Patients with AS
-
4m 14sPart 3 | Session 3 SMART-CHOICE 3: Clopidogrel vs Aspirin Monotherapy in High-Risk PCI Patients
-
9m 39s
-
2m 54s
-
4m 58sPart 3 | Session 6 MIGHTy-Heart: Mobile Integrated Health in Heart Failure
-
7m 33s
-
2m 46s
-
6m 34s
-
2m 46sPart 3 | Session 10 Lifetime Benefit by Control of Modifiable Risk Factors
-
10m 27sPart 3 | Session 11 CardiAMP-HF: Autologous Cell Therapy in Patients With HFrEF
-
3mPart 4 | Session 1 4 Trials That Will Change My Practice with Dr Ambarish Pandey
-
4m 27sPart 4 | Session 2 4 Trials That Will Change My Practice with Dr Dipti Itchhaporia
-
30m 45sPart 1 | Session 1 View from the Thoraxcenter: What's Hot at ACC.25?
-
39m 2sPart 1 | Session 2 View from the Thoraxcenter: ACC 25 Wrap-Up
-
17m 26sPart 2 | Session 1 ADVANCE-HTN: Lorundrostat in Patients with Uncontrolled Hypertension
-
11m 44sPart 2 | Session 2 STRIDE: Semaglutide for Functional Capacity in Patients with T2D and PAD
-
12m 9sPart 2 | Session 3 API-CAT: Reduced Vs Full Dose Apixaban for Cancer-Associated Thrombosis
-
14m 1sPart 2 | Session 4 FRESH-UP: Liberal Intake Vs Fluid Restriction in Chronic Heart Failure
ACC 25 - SOUL shows oral semaglutide was superior to placebo in reducing the incidence of 3-point MACE in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease.
Late-breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Darren McGuire (UT Southwestern Medical Center, Dallas, US) to discuss the findings from the large-scale SOUL trial, which investigated the impact of oral semaglutide on type 2 diabetes patients with prior cardiovascular or chronic kidney disease. Patients were randomized 1:1 to recieve either a daily oral semaglutide tablet (3mg/7mg/14mg titration) or an oral placebo tablet. The primary outcome was time to first occurence of MACE, whilst secondary outcomes included a composite of renal outcomes, major adverse limb outcomes, heart failure outcomes, all-cause mortality, changes in HbA1c and body weight, and hypoglycemia episodes.
Findings showed that oral semaglutide had proven cardiovascular benefits, with consistent cardiovascular efficacy across subgroups by sex, age, BMI, eGFR and concomitant medication.
Recorded onsite at ACC 2025, Chicago.
Editors: Jordan Rance, Yazmin Sadik
Videographers: Dan Brent, David Ben-Harosh
Support: This is an independent interview produced by Radcliffe CVRM.
Keep up-to-date with our video collection on the American College of Cardiology's 74th annual congress, covering late-breaking science, featured science and clinical horizon sessions. Don't miss the preview and wrap-up of the congress in our View From the Thoraxcenter series, concise Expert Interviews with select faculty offering take-home messages for practice, and our Highlights summarising the most influential trials.
More from this programme
Part 1
View From the Thoraxcenter
Part 2
Late-Breaker Discussion Series
Part 3
Expert Interviews
Faculty Biographies
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an internationally known cardiologist, research methodologist, and senior scientist. She serves as an Associate Professor of Medicine at McMaster University, a Senior Scientist at the Population Health Research Institute, and Director of Implementation Science at the Baim Institute for Clinical Research in Boston.
Academic history
Dr Van Spall completed her BSc and MD at the University of Toronto, followed by residency and fellowship training in internal medicine and…
Comments